Local life sciences companies like Moderna Inc. and Takeda Pharmaceuticals Inc. are leaning into AI to help employees work ...

Moderna's mRNA platform now features a long list of candidates, and the biotech still has enough cash on hand -- $12.2 ...

Moderna has won U.S. Food and Drug Administration approval for its respiratory syncytial virus vaccine mResvia, ushering in a new era for the ...

Flagship scours labs, research hospitals, and universities for cutting-edge science and builds companies around that science.

The stock's fall snapped a two-day winning streak.

The US Department of Health and Human Services announced Tuesday a contract with Moderna to develop an mRNA vaccine that ...

Philadelphia-based Carisma Therapeutics has chosen an experimental cell therapy that targets the most prevalent type of liver ...

Some investors might view biotech company Moderna (Nasdaq: MRNA) as a shooting star that shone brightly for a while, then ...

There have been four human cases of bird flu in the U.S., including three in 2024. Over 130 cow herds in 12 states have seen ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines looks set to continue after London's High Court gave a ...

The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine ...

Moderna Inc. closed $54.02 short of its 52-week high ($170.47), which the company reached on May 24th.